Proton Pump Inhibitor Use and Iron Deficiency Anemia in Celiac Patients.

INTRODUCTION: We sought to evaluate the effect of PPI (proton pump inhibitor) use on the development and severity of iron deficiency anemia (IDA) in celiac disease (CD).

METHODS: We conducted a retrospective chart review of patients older than 18 years of age at Milton S. Hershey Medical Center who were diagnosed with CD. We analyzed four cohorts of celiac patients (1) IDA diagnosis with PPI usage, (2) no IDA diagnosis with PPI usage, (3) IDA diagnosis with no PPI usage, and (4) no IDA diagnosis with no PPI usage. We also stratified celiac patients with IDA by anemia severity.

RESULTS: Of 366 celiac patients, 92(25.1%) were diagnosed with IDA, of which 60(65.2%) were on a PPI. The mean Hgb of celiac patients with IDA on a PPI was 11.1 g/dL and 12.1 g/dL for those without PPI (p=0.04). For all celiac patients on a PPI without IDA, the mean was 13.3 g/dL and 13.7 g/dL for those without PPI (p=0.02). PPI use occurred in 12(70.6%) of the 17 patients with low severity anemia, 11(64.7%) of the 17 patients with medium severity and 6(85.7%) of the 7 patients with severe (p=0.55).

CONCLUSIONS: There is significant association between PPI use and IDA in celiac patients (p<0.0001). Of those with IDA on PPIs, the distribution of the severity of anemia is not statistically different compared to those not on PPI. Discontinuation of PPIs or usage of alternative acid suppressive treatments may be indicated in patients with celiac disease and iron deficiency anemia.